[{"indications": "Indications\u00a0mild to moderate plaque psoriasis affecting\r\nup to 10% of skin area", "name": "TAZAROTENE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.5 Preparations for eczema and psoriasis", "13.5.2 Preparations for psoriasis", "Topical preparations for psoriasis", "Tazarotene"], "cautions": "Cautions\u00a0wash hands immediately after use, avoid contact with eyes, face, intertriginous areas, hair-covered\r\nscalp, eczematous or inflamed skin; avoid excessive exposure to UV light (including sunlight,\r\nsolariums, PUVA or UVB treatment); do not\r\napply emollients or cosmetics within 1 hour of application", "side-effects": "Side-effects\u00a0local irritation (more common with higher concentration\r\nand may require discontinuation), pruritus, burning, erythema, desquamation,\r\nnon-specific rash, contact dermatitis, and worsening of psoriasis;\r\nrarely stinging and inflamed, dry or painful skin", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/66074.htm", "doses": ["Apply once daily in the evening usually for up to 12 weeks; child under 18 years not recommended"], "pregnancy": "Pregnancy\u00a0avoid; effective contraception required (oral progestogen-only\r\ncontraceptives not considered effective)"}]